0 CHECKOUT

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015

  • ID: 3422669
  • August 2015
  • 104 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Akron Molecules AG
  • AstraZeneca Plc
  • Bayer AG
  • Celon Pharma Sp. z o.o.
  • Pfizer Inc.
  • Sareum Holdings Plc
  • MORE

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015

Summary

The report ‘Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015’, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Akron Molecules AG
  • AstraZeneca Plc
  • Bayer AG
  • Celon Pharma Sp. z o.o.
  • Pfizer Inc.
  • Sareum Holdings Plc
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Anaplastic Large Cell Lymphoma (ALCL) Overview

Therapeutics Development

Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview

Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis

Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies

Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Investigation by Universities/Institutes

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies

Anaplastic Large Cell Lymphoma (ALCL) - Products under Investigation by Universities/Institutes

Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development

Akron Molecules AG

AstraZeneca Plc

Bayer AG

Celon Pharma Sp. z o.o.

Pfizer Inc.

Sareum Holdings Plc

Seattle Genetics, Inc.

Teva Pharmaceutical Industries Limited

Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AdIL-24 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AKR-302 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AKR-303 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AZD-3463 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brentuximab vedotin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CEP-28122 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CEP-37440 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

copanlisib hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

crizotinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KRA-0008 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SH-7129 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Anaplastic Large Cell Lymphoma (ALCL) - Recent Pipeline Updates

Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects

Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products

Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones

Featured News & Press Releases

Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting

Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting

Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014

Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting

Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress

Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan

Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma

Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2015

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Akron Molecules AG, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca Plc, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings Plc, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Recent Pipeline Updates, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2015

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Akron Molecules AG
AstraZeneca Plc
Bayer AG
Celon Pharma Sp. z o.o.
Pfizer Inc.
Sareum Holdings Plc
Seattle Genetics, Inc.
Teva Pharmaceutical Industries Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline PLC
  • Accuray Incorporated
  • Becton, Dickinson and Company (BD)
  • Novartis AG
  • Elekta AB